Trial · NCT07165886
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 21
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Phase II: Incidences of Adeverse Events (AEs) | Up to 3 years | |
| Primary | Phase II: Dose Limiting Toxicity (DLT) | Up to 1 year | |
| Primary | Phase II: Recommended Phase 3 Dose (RP3D) | Up to 1 year | |
| Primary | Phase II: Objective Response Rate (ORR） per investigator | Up to 1 year | |
| Primary | Phase III: Progression Free Survival (PFS) per Blinded Independent Review Committee (BIRC) | Up to 3 years | |
| Secondary | Phase II: Duration of Response (DOR) per investigator | Up to 3 years | |
| Secondary | Phase II: Disease Control Rate (DCR) per investigator | Up to 3 years | |
| Secondary | Phase II: Progression Free Survival (PFS) per investigator | Up to 3 years | |
| Secondary | Phase II: Overall Survival (OS) | Up to 3 years | |
| Secondary | Peak Concentration：Cmax | Up to 3 years | |
| Secondary | Area under the plasma concentration-time curve: AUC | Up to 3 years | |
| Secondary | Half-Life: t1/2 | Up to 3 years | |
| Secondary | Phase II: Blood concentrations and PK parameters of sirolimus for injection(albumin bound) and Octreotide long-acting injection. | From first dose of treatment to C3D15 | |
| Secondary | Phase II: Changes in serum chromogranin A, 24-hour urinary 5-hydroxyindoleacetic acid, and serum IGF-1 levels from baseline. | From first dose of treatment to end of treatment | |
| Secondary | Phase III: Progression Free Survival (PFS) per investigator | Up to 3 years | |
| Secondary | Phase III: Objective Response Rate (ORR） | Up to 3 years | |
| Secondary | Phase III: Duration of Response (DOR) | Up to 3 years | |
| Secondary | Phase III: Disease Control Rate (DCR) | Up to 3 years | |
| Secondary | Phase III: Incidences of Adeverse Events (AEs) | Up to 3 years | |
| Secondary | Phase III: Overall Survival (OS) | Up to 3 years |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07165886/registered